Buy & Sell Robinhood Markets, Inc. (HOOD) – Robinhood Markets, Inc. Price Today
Aura AI Summary
Key Stats
- $97.39BMarket Cap
- TechnologySector
- -21.99%3M Drawdown
- $98.59BEnterprise Value
- -Dividend Yield
- 50% Buy | 50% SellTrading Activity
- 69 daysTypical Hold Time
Robinhood Markets, Inc. (HOOD) is currently valued at a market capitalization of $97.39B, with an enterprise value of $98.59B. Over the past 52 weeks, Robinhood Markets, Inc. has traded between a low of $65.16 and a high of $152.46, highlighting its annual price range. Over the past three months, Robinhood Markets, Inc. has recorded a drawdown of -21.99%, reflecting recent price volatility. On average, investors hold Robinhood Markets, Inc. for approximately 69 days, indicating typical investor behavior on the platform.
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Most Recent News
Tourism surges at Hengdian World Studios as Pursuit of Jade tops global C-drama charts.
Hengdian World Studios saw a major spike in visitors after the Chinese drama Pursuit of Jade, filmed mostly at the studio, topped international streaming charts and search volumes in 15 countries. During the May holiday, over 80,000 tourists visited ...

Global sputtering equipment market to reach $4.19B by 2035, driven by semiconductor and solar industry growth.
The global sputtering equipment market is projected to grow from USD 2.41 billion in 2025 to USD 4.19 billion by 2035, at a CAGR of 5.83%. Growth is fueled by rising demand for high-performance semiconductors, flat panel displays, and photovoltaic so...

Japan approves Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
